[{"id":"67808c71-e5cd-4a23-b8c3-03e45ed11d23","acronym":"","url":"https://clinicaltrials.gov/study/NCT00084422","created_at":"2021-01-18T00:14:29.115Z","updated_at":"2024-07-02T16:35:51.014Z","phase":"Phase 1","brief_title":"N2001-03: CEP-701 in Treating Young Patients With Recurrent or Refractory High-Risk Neuroblastoma","source_id_and_acronym":"NCT00084422","lead_sponsor":"New Approaches to Neuroblastoma Therapy Consortium","biomarkers":" NTRK2","pipe":"","alterations":" ","tags":["NTRK2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lestaurtinib (CEP-701)"],"overall_status":"Completed","enrollment":" Enrollment 47","initiation":"Initiation: 08/01/2003","start_date":" 08/01/2003","primary_txt":" Primary completion: 09/01/2009","primary_completion_date":" 09/01/2009","study_txt":" Completion: 02/01/2011","study_completion_date":" 02/01/2011","last_update_posted":"2023-04-10"},{"id":"62d7e73e-6c60-4204-8c20-9c3baeb93f7b","acronym":"","url":"https://clinicaltrials.gov/study/NCT00469859","created_at":"2021-01-18T01:40:14.344Z","updated_at":"2024-07-02T16:37:24.369Z","phase":"Phase 1/2","brief_title":"Lestaurtinib, Cytarabine, and Idarubicin in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia","source_id_and_acronym":"NCT00469859","lead_sponsor":"Children's Oncology Group","biomarkers":" FLT3","pipe":"","alterations":" ","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • idarubicin hydrochloride • lestaurtinib (CEP-701)"],"overall_status":"Completed","enrollment":" Enrollment 14","initiation":"Initiation: 06/01/2007","start_date":" 06/01/2007","primary_txt":" Primary completion: 03/01/2010","primary_completion_date":" 03/01/2010","study_txt":" Completion: 03/01/2010","study_completion_date":" 03/01/2010","last_update_posted":"2017-03-15"}]